Events & presentations

Internal link Conference call additional sepofarsen analyses and company strategy update

ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).

• Add Conference call additional sepofarsen analyses and company strategy update to calender

Internal link Conference call top-line results Phase 2/3 Illuminate trial

ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.

• Add Conference call top-line results Phase 2/3 Illuminate trial to calender

Internal link ProQR Analyst Event

During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

• Add ProQR Analyst Event to calender

Internal link Axiomer Investor Call

ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly. 

• Add Axiomer Investor Call to calender

Internal link Annual General Meeting (virtual)

The 2021 annual general meeting (AGM) of shareholders of ProQR Therapeutics
will take place on Wednesday, May 19, 2021, at 16:00 hours CET/10:00am EDT.

• Add Annual General Meeting (virtual) to calender